Novartis Phase III Pelacarsen Trial Misses Primary Endpoint in 8,000+ Patients

Novartis' phase III trial of pelacarsen, an antisense therapy targeting lipoprotein(a), failed to show a significant reduction in major cardiovascular events despite effectively lowering Lp(a) levels. The result is a setback for the drug's development and for the Lp(a) hypothesis, though the full data may still reveal subgroup benefits. This could impact Novartis' pipeline valuation and the broader cardiovascular drug development landscape.